CytomX Therapeutics, Inc. (CTMX) financial statements (2022 and earlier)

Company profile

Business Address 151 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:266,349256,298296,145436,127374,110181,900186,700
Cash and cash equivalents205,530191,859188,425247,577177,548104,64559,822
Short-term investments99,696124,260107,720188,550196,56277,293126,889
Other undisclosed cash, cash equivalents, and short-term investments(38,877)(59,821)   (38)(11)
Receivables790798139710,1392,313744
Other undisclosed current assets43,16266,9177,1779,2514,3523,9342,310
Total current assets:310,301324,013303,335445,475388,601188,147189,754
Noncurrent Assets
Operating lease, right-of-use asset19,36222,49525,382
Property, plant and equipment5,9606,9507,3726,9344,2184,3923,481
Intangible assets, net (including goodwill)1,9702,1162,2612,4072,5532,6992,699
Goodwill949949949949949949949
Intangible assets, net (excluding goodwill)1,0211,1671,3121,4581,6041,7501,750
Restricted cash and investments917917917917917917917
Other noncurrent assets9012,1722,0151,3751,3552,973364
Total noncurrent assets:29,11034,65037,94711,6339,04310,9817,461
TOTAL ASSETS:339,411358,663341,282457,108397,644199,128197,215
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37,05426,05534,20945,19520,58815,4209,609
Accounts payable2,8182,9964,1585,1324,2056,5964,697
Accrued liabilities34,23623,05930,05126,72416,3838,8244,912
Taxes payable   13,339   
Deferred revenue69,26274,86951,381
Deferred revenue and credits40,55920,3476,130
Contract with customer, liability52,713
Total current liabilities:106,316100,92485,59097,90861,14735,76715,739
Noncurrent Liabilities
Long-term debt and lease obligation18,05621,67524,871    
Operating lease, liability18,05621,67524,871
Liabilities, other than long-term debt125,660186,261179,708228,317266,60184,88255,408
Deferred revenue and credits264,70483,80354,703
Deferred revenue125,660186,261178,858
Contract with customer, liability225,267
Deferred tax liabilities, net  513507
Other liabilities  8503,0501,897566198
Total noncurrent liabilities:143,716207,936204,579228,317266,60184,88255,408
Total liabilities:250,032308,860290,169326,225327,748120,64971,147
Stockholders' equity
Stockholders' equity attributable to parent, including:89,37949,80351,113130,88369,89678,479126,068
Common stock1111111
Additional paid in capital623,344499,964468,285445,956289,454254,871243,687
Accumulated other comprehensive income (loss)(242)(47)57(93)(94)(27)(76)
Accumulated deficit(533,724)(450,115)(417,230)(314,981)(219,465)(176,366)(117,466)
Other undisclosed stockholders' equity attributable to parent      (78)
Total stockholders' equity:89,37949,80351,113130,88369,89678,479126,068
TOTAL LIABILITIES AND EQUITY:339,411358,663341,282457,108397,644199,128197,215

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues69,573100,36257,48959,50271,62315,0437,712
Revenue, net71,62315,043 
Gross profit:69,573100,36257,48959,50271,62315,0437,712
Operating expenses(153,354)(148,967)(168,384)(137,376)(117,882)(74,629)(40,915)
Operating loss:(83,781)(48,605)(110,895)(77,874)(46,259)(59,586)(33,203)
Nonoperating income (expense)1721,8098,2307,5732,6472,356(429)
Investment income, nonoperating2551,8368,3657,6412,6742,4251,315
Other nonoperating expense(83)(27)(135)(68)(27)(69)(1,744)
Interest and debt expense     (1,689)(1,732)
Loss from continuing operations before income taxes:(83,609)(46,796)(102,665)(70,301)(43,612)(58,919)(35,364)
Income tax expense (benefit) 13,911427(14,303)51319(10)
Net loss attributable to parent:(83,609)(32,885)(102,238)(84,604)(43,099)(58,900)(35,374)
Preferred stock dividends and other adjustments      (6,705)
Net loss available to common stockholders, diluted:(83,609)(32,885)(102,238)(84,604)(43,099)(58,900)(42,079)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(83,609)(32,885)(102,238)(84,604)(43,099)(58,900)(35,374)
Other comprehensive income (loss)   1(67)49(76)
Comprehensive loss:(83,609)(32,885)(102,238)(84,603)(43,166)(58,851)(35,450)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(195)(104)150    
Comprehensive loss, net of tax, attributable to parent:(83,804)(32,989)(102,088)(84,603)(43,166)(58,851)(35,450)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: